作者
- Califf, R.M. (18)
- Granger, C.B. (15)
- Maggioni, A.P. (10)
- McMurray, J.J.V. (51)
- Michelson, E.L. (11)
- Pfeffer, M.A. (25)
- Solomon, S.D. (14)
- Swedberg, K. (12)
- Velazquez, E.J. (15)
- Yusuf, S. (11)
|
總筆數:51
| 篇名 | 作者 | 刊名 | 出版年 | 查看 |
|---|
| ADEPT: Addition of the AT"1 receptor antagonist eprosartan to ACE inhibitortherapy in chronic heart failure trial: Hemodynamic and neurohormonaleffects |
Murdoch, D.R.;McDonagh, T.A.;Farmer, R.;Morton, J.J.;McMurray, J.J.V.;Dargie, H.J.; |
American Heart Journal |
2001-05-01 |
查看 |
| ADEPT: Addition of the AT"1 receptor antagonist eprosartan to ACE inhibitortherapy in chronic heart failure trial: Hemodynamic and neurohormonaleffects |
Murdoch, D.R.;McDonagh, T.A.;Farmer, R.;Morton, J.J.;McMurray, J.J.V.;Dargie, H.J.; |
American Heart Journal |
2001-05-01 |
查看 |
| ADEPT: Addition of the AT"1 receptor antagonist eprosartan to ACEinhibitor therapy in chronic heart failure trial: Hemodynamic andneurohormonal effects |
Murdoch, D.R.;McDonagh, T.A.;Farmer, R.;Morton, J.J.;McMurray, J.J.V.;Dargie, H.J.; |
American Heart Journal |
2001-05-01 |
查看 |
| ADEPT: Addition of the AT"1 receptor antagonist eprosartan to ACEinhibitor therapy in chronic heart failure trial: Hemodynamic andneurohormonal effects |
Murdoch, D.R.;McDonagh, T.A.;Farmer, R.;Morton, J.J.;McMurray, J.J.V.;Dargie, H.J.; |
American Heart Journal |
2001-05-01 |
查看 |
| Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy(TREAT): Evolving the management of cardiovascular risk in patients withchronic kidney disease |
Mix, T.-C.H.;Brenner, R.M.;Cooper, M.E.;de Zeeuw, D.;Ivanovich, P.;Levey, A.S.;McGill, J.B.;McMurray, J.J.V.;Parfrey, P.S.;Parving, H.-H.;Pereira, B.J.G.;Remuzzi, G.;Singh, A.K.;Solomon, S.D.;Stehman-Breen, C.;Toto, R.D.;Pfeffer, M.A.; |
American Heart Journal |
2005-03-01 |
查看 |
| Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy(TREAT): Evolving the management of cardiovascular risk in patients withchronic kidney disease |
Mix, T.-C.H.;Brenner, R.M.;Cooper, M.E.;de Zeeuw, D.;Ivanovich, P.;Levey, A.S.;McGill, J.B.;McMurray, J.J.V.;Parfrey, P.S.;Parving, H.-H.;Pereira, B.J.G.;Remuzzi, G.;Singh, A.K.;Solomon, S.D.;Stehman-Breen, C.;Toto, R.D.;Pfeffer, M.A.; |
American Heart Journal |
2005-03-01 |
查看 |
| Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy(TREAT): Evolving the management of cardiovascular risk in patients withchronic kidney disease |
Mix, T.C.H.;Brenner, R.M.;Cooper, M.E.;de Zeeuw, D.;Ivanovich, P.;Levey, A.S.;McGill, J.B.;McMurray, J.J.V.;Parfrey, P.S.;Parving, H.H.;Pereira, B.J.G.;Remuzzi, G.;Singh, A.K.;Solomon, S.D.;Stehman-Breen, C.;Toto, R.D.;Pfeffer, M.A.; |
American Heart Journal |
2005-03-01 |
查看 |
| Tezosentan in patients with acute heart failure: Design of the Value ofEndothelin Receptor Inhibition with Tezosentan in Acute heart failure Study(VERITAS) |
VERITAS Investigators;Teerlink, J.R.;McMurray, J.J.V.;Bourge, R.C.;Cleland, J.G.F.;Cotter, G.;Jondeau, G.;Krum, H.;Metra, M.;O'Connor, C.M.;Parker, J.D.;Torre-Amione, G.;Van Veldhuisen, D.J.;Frey, A.;Rainisio, M.;Kobrin, I.; |
American Heart Journal |
2005-07-01 |
查看 |
| Tezosentan in patients with acute heart failure: Design of the Value ofEndothelin Receptor Inhibition with Tezosentan in Acute heart failure Study(VERITAS) |
VERITAS Investigators;Teerlink, J.R.;McMurray, J.J.V.;Bourge, R.C.;Cleland, J.G.F.;Cotter, G.;Jondeau, G.;Krum, H.;Metra, M.;O'Connor, C.M.;Parker, J.D.;Torre-Amione, G.;Van Veldhuisen, D.J.;Frey, A.;Rainisio, M.;Kobrin, I.; |
American Heart Journal |
2005-07-01 |
查看 |
| Resource use, costs, and quality of life among patients in themultinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) |
for the VALIANT Investigators;Reed, S.D.;Radeva, J.I.;Weinfurt, K.P.;McMurray, J.J.V.;Pfeffer, M.A.;Velazquez, E.J.;Allsbrook, J.S.;Masselink, L.E.;Sellers, M.A.;Califf, R.M.;Schulman, K.A.; |
American Heart Journal |
2005-08-01 |
查看 |
| Resource use, costs, and quality of life among patients in themultinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) |
for the VALIANT Investigators;Reed, S.D.;Radeva, J.I.;Weinfurt, K.P.;McMurray, J.J.V.;Pfeffer, M.A.;Velazquez, E.J.;Allsbrook, J.S.;Masselink, L.E.;Sellers, M.A.;Califf, R.M.;Schulman, K.A.; |
American Heart Journal |
2005-08-01 |
查看 |
| The cost of acute myocardial infarction in the new millennium: Evidencefrom a multinational registry |
Kauf, T.L.;Velazquez, E.J.;Crosslin, D.R.;Weaver, W.D.;Diaz, R.;Granger, C.B.;McMurray, J.J.V.;Rouleau, J.L.;Aylward, P.E.;White, H.D.;Califf, R.M.;Schulman, K.A.; |
American Heart Journal |
2006-01-01 |
查看 |
| The cost of acute myocardial infarction in the new millennium: Evidencefrom a multinational registry |
Kauf, T.L.;Velazquez, E.J.;Crosslin, D.R.;Weaver, W.D.;Diaz, R.;Granger, C.B.;McMurray, J.J.V.;Rouleau, J.L.;Aylward, P.E.;White, H.D.;Califf, R.M.;Schulman, K.A.; |
American Heart Journal |
2006-01-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Yusuf, S.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| The prevalence, nature, and importance of hematologic abnormalities inheart failure |
Berry, C.;Norrie, J.;Hogg, K.;Brett, M.;Stevenson, K.;McMurray, J.J.V.; |
American Heart Journal |
2006-06-01 |
查看 |
| The prevalence, nature, and importance of hematologic abnormalities inheart failure |
Berry, C.;Norrie, J.;Hogg, K.;Brett, M.;Stevenson, K.;McMurray, J.J.V.; |
American Heart Journal |
2006-06-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Extent of coronary artery disease as a predictor of outcomes in acutemyocardial infarction complicated by heart failure, left ventriculardysfunction, or both |
for the VALIANT Investigators;Janardhanan, R.;Kenchaiah, S.;Velazquez, E.J.;Park, Y.;McMurray, J.J.V.;Weaver, W.D.;Finn, P.V.;White, H.D.;Marin-Neto, J.A.;O'Connor, C.;Pfeffer, M.A.;Califf, R.M.;Solomon, S.D.; |
American Heart Journal |
2006-07-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Extent of coronary artery disease as a predictor of outcomes in acutemyocardial infarction complicated by heart failure, left ventriculardysfunction, or both |
for the VALIANT Investigators;Janardhanan, R.;Kenchaiah, S.;Velazquez, E.J.;Park, Y.;McMurray, J.J.V.;Weaver, W.D.;Finn, P.V.;White, H.D.;Marin-Neto, J.A.;O'Connor, C.;Pfeffer, M.A.;Califf, R.M.;Solomon, S.D.; |
American Heart Journal |
2006-07-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Extent of coronary artery disease as a predictor of outcomes in acutemyocardial infarction complicated by heart failure, left ventriculardysfunction, or both |
for the VALIANT Investigators;Janardhanan, R.;Kenchaiah, S.;Velazquez, E.J.;Park, Y.;McMurray, J.J.V.;Weaver, W.D.;Finn, P.V.;White, H.D.;Marin-Neto, J.A.;O'Connor, C.;Pfeffer, M.A.;Califf, R.M.;Solomon, S.D.; |
American Heart Journal |
2006-07-01 |
查看 |
| Geographic variation in the treatment of acute myocardial infarction inthe VALsartan In Acute myocardial iNfarcTion (VALIANT) trial |
for the VALIANT Committees and Investigators;Reed, S.D.;McMurray, J.J.V.;Velazquez, E.J.;Schulman, K.A.;Califf, R.M.;Kober, L.;Maggioni, A.P.;Van de Werf, F.;White, H.D.;Diaz, R.;Mareev, V.;Murin, J.; |
American Heart Journal |
2006-09-01 |
查看 |
| Geographic variation in the treatment of acute myocardial infarction inthe VALsartan In Acute myocardial iNfarcTion (VALIANT) trial |
for the VALIANT Committees and Investigators;Reed, S.D.;McMurray, J.J.V.;Velazquez, E.J.;Schulman, K.A.;Califf, R.M.;Kober, L.;Maggioni, A.P.;Van de Werf, F.;White, H.D.;Diaz, R.;Mareev, V.;Murin, J.; |
American Heart Journal |
2006-09-01 |
查看 |
| Geographic variation in the treatment of acute myocardial infarction inthe VALsartan In Acute myocardial iNfarcTion (VALIANT) trial |
for the VALIANT Committees and Investigators;Reed, S.D.;McMurray, J.J.V.;Velazquez, E.J.;Schulman, K.A.;Califf, R.M.;Kober, L.;Maggioni, A.P.;Van de Werf, F.;White, H.D.;Diaz, R.;Mareev, V.;Murin, J.; |
American Heart Journal |
2006-09-01 |
查看 |
| Amiodarone use after acute myocardial infarction complicated by heartfailure and/or left ventricular dysfunction may be associated with excessmortality |
Thomas, K.L.;Al-Khatib, S.M.;Lokhnygina, Y.;Solomon, S.D.;Kober, L.;McMurray, J.J.V.;Califf, R.M.;Velazquez, E.J.; |
American Heart Journal |
2008-01-01 |
查看 |
| Amiodarone use after acute myocardial infarction complicated by heartfailure and/or left ventricular dysfunction may be associated with excessmortality |
Thomas, K.L.;Al-Khatib, S.M.;Lokhnygina, Y.;Solomon, S.D.;Kober, L.;McMurray, J.J.V.;Califf, R.M.;Velazquez, E.J.; |
American Heart Journal |
2008-01-01 |
查看 |
| Rationale and design of the dal-OUTCOMES trial: Efficacy and safety ofdalcetrapib in patients with recent acute coronary syndrome |
on behalf of the dal-OUTCOMES Committees and Investigators;Schwartz, G.G.;Olsson, A.G.;Ballantyne, C.M.;Barter, P.J.;Holme, I.M.;Kallend, D.;Leiter, L.A.;Leitersdorf, E.;McMurray, J.J.V.;Shah, P.K.;Tardif, J.C.;Chaitman, B.R.;Duttlinger-Maddux, R.;Mathieson, J.; |
American Heart Journal |
2009-12-01 |
查看 |
| Apixaban for Reduction In Stroke and Other ThromboemboLic Events inAtrial Fibrillation (ARISTOTLE) trial: Design and rationale |
on behalf of the ARISTOTLE Investigators;Lopes, R.D.;Alexander, J.H.;Al-Khatib, S.M.;Ansell, J.;Diaz, R.;Easton, J.D.;Gersh, B.J.;Granger, C.B.;Hanna, M.;Horowitz, J.;Hylek, E.M.;McMurray, J.J.V.;Verheugt, F.W.A.;Wallentin, L.; |
American Heart Journal |
2010-03-01 |
查看 |
| Apixaban for Reduction In Stroke and Other ThromboemboLic Events inAtrial Fibrillation (ARISTOTLE) trial: Design and rationale |
on behalf of the ARISTOTLE Investigators;Lopes, R.D.;Alexander, J.H.;Al-Khatib, S.M.;Ansell, J.;Diaz, R.;Easton, J.D.;Gersh, B.J.;Granger, C.B.;Hanna, M.;Horowitz, J.;Hylek, E.M.;McMurray, J.J.V.;Verheugt, F.W.A.;Wallentin, L.; |
American Heart Journal |
2010-03-01 |
查看 |
| Fatal myocardial rupture after acute myocardial infarction complicatedby heart failure, left ventricular dysfunction, or both: The VALsartan InAcute myocardial iNfarcTion Trial (VALIANT) |
for the VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial;Investigators;Shamshad, F.;Kenchaiah, S.;Finn, P.V.;Soler-Soler, J.;McMurray, J.J.V.;Velazquez, E.J.;Maggioni, A.P.;Califf, R.M.;Swedberg, K.;Kober, L.;Belenkov, Y.;Varshavsky, S.;Pfeffer, M.A.;Solomon, S.D.; |
American Heart Journal |
2010-07-01 |
查看 |
| Incremental value of echocardiographic assessment beyond clinicalevaluation for prediction of death and development of heart failure afterhigh-risk myocardial infarction |
Verma, A.;Pfeffer, M.A.;Skali, H.;Rouleau, J.;Maggioni, A.;McMurray, J.J.V.;Califf, R.M.;Velazquez, E.J.;Solomon, S.D.; |
American Heart Journal |
2011-06-01 |
查看 |
| Cardiac structure and function, remodeling, and clinical outcomes amongpatients with diabetes after myocardial infarction complicated by leftventricular systolic dysfunction, heart failure, or both |
Shah, A.M.;Hung, C.L.;Shin, S.H.;Skali, H.;Verma, A.;Ghali, J.K.;Kober, L.;Velazquez, E.J.;Rouleau, J.L.;McMurray, J.J.V.;Pfeffer, M.A.;Solomon, S.D.; |
American Heart Journal |
2011-10-01 |
查看 |
| Predictors of fatal and nonfatal cardiovascular events in patients withtype 2 diabetes mellitus, chronic kidney disease, and anemia: An analysisof the Trial to Reduce cardiovascular Events with Aranesp(darbepoetin-alfa) Therapy (TREAT) |
McMurray, J.J.V.;Uno, H.;Jarolim, P.;Desai, A.S.;de Zeeuw, D.;Eckardt, K.U.;Ivanovich, P.;Levey, A.S.;Lewis, E.F.;McGill, J.B.;Parfrey, P.;Parving, H.H.;Toto, R.M.;Solomon, S.D.;Pfeffer, M.A.; |
American Heart Journal |
2011-10-01 |
查看 |
| Intensive glycemic control has no impact on the risk of heart failurein type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis |
Castagno, D.;Baird-Gunning, J.;Jhund, P.S.;Biondi-Zoccai, G.;MacDonald, M.R.;Petrie, M.C.;Gaita, F.;McMurray, J.J.V.; |
American Heart Journal |
2011-11-01 |
查看 |
| Days alive and out of hospital and the patient journey in patients withheart failure: Insights from the Candesartan in Heart failure: Assessmentof Reduction in Mortality and morbidity (CHARM) program |
Ariti, C.A.;Cleland, J.G.F.;Pocock, S.J.;Pfeffer, M.A.;Swedberg, K.;Granger, C.B.;McMurray, J.J.V.;Michelson, E.L.;Ostergren, J.;Yusuf, S.; |
American Heart Journal |
2011-11-01 |
查看 |
| Intensive glycemic control has no impact on the risk of heart failurein type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis |
Castagno, D.;Baird-Gunning, J.;Jhund, P.S.;Biondi-Zoccai, G.;MacDonald, M.R.;Petrie, M.C.;Gaita, F.;McMurray, J.J.V.; |
American Heart Journal |
2011-11-01 |
查看 |
| Days alive and out of hospital and the patient journey in patients withheart failure: Insights from the Candesartan in Heart failure: Assessmentof Reduction in Mortality and morbidity (CHARM) program |
Ariti, C.A.;Cleland, J.G.F.;Pocock, S.J.;Pfeffer, M.A.;Swedberg, K.;Granger, C.B.;McMurray, J.J.V.;Michelson, E.L.;Ostergren, J.;Yusuf, S.; |
American Heart Journal |
2011-11-01 |
查看 |
| Reply to the letter by Dr Erqou regarding ''Intensive glycemic controlhas no impact on the risk of heart failure in type 2 diabetic patients'' |
Castagno, D.;Baird-Gunning, J.;Jhund, P.S.;Zoccai, G.B.;MacDonald, M.R.;Petrie, M.C.;Gaita, F.;McMurray, J.J.V.; |
American Heart Journal |
2012-05-01 |
查看 |
| The predictive value of galectin-3 for mortality and cardiovascularevents in the Controlled Rosuvastatin Multinational Trial in Heart Failure(CORONA) |
Gullestad, L.;Ueland, T.;Kjekshus, J.;Nymo, S.H.;Hulthe, J.;Muntendam, P.;McMurray, J.J.V.;Wikstrand, J.;Aukrust, P.; |
American Heart Journal |
2012-12-01 |
查看 |
| Incidence of atrial fibrillation in a population with impaired glucosetolerance: The contribution of glucose metabolism and other risk factors. Apost hoc analysis of the Nateglinide and Valsartan in Impaired GlucoseTolerance Outcomes Research trial |
Latini, R.;Staszewsky, L.;Sun, J.L.;Bethel, M.A.;Disertori, M.;Haffner, S.M.;Holman, R.R.;Chang, F.;Giles, T.D.;Maggioni, A.P.;Rutten, G.E.H.M.;Standl, E.;Thomas, L.;Tognoni, G.;Califf, R.M.;McMurray, J.J.V.; |
American Heart Journal |
2013-11-01 |
查看 |
| Incidence of atrial fibrillation in a population with impaired glucosetolerance: The contribution of glucose metabolism and other risk factors. Apost hoc analysis of the Nateglinide and Valsartan in Impaired GlucoseTolerance Outcomes Research trial |
Latini, R.;Staszewsky, L.;Sun, J.L.;Bethel, M.A.;Disertori, M.;Haffner, S.M.;Holman, R.R.;Chang, F.;Giles, T.D.;Maggioni, A.P.;Rutten, G.E.H.M.;Standl, E.;Thomas, L.;Tognoni, G.;Califf, R.M.;McMurray, J.J.V.; |
American Heart Journal |
2013-11-01 |
查看 |
| Predictors of clinical outcomes in acute decompensated heart failure:Acute Study of Clinical Effectiveness of Nesiritide in Decompensated HeartFailure outcome models |
Khazanie, P.;Heizer, G.M.;Hasselblad, V.;Armstrong, P.W.;Califf, R.M.;Ezekowitz, J.;Dickstein, K.;Levy, W.C.;McMurray, J.J.V.;Metra, M.;Wilson Tang, W.H.;Teerlink, J.R.;Voors, A.A.;O'Connor, C.M.;Hernandez, A.F.;Starling, R.; |
American Heart Journal |
2015-08-01 |
查看 |
| Predictors of clinical outcomes in acute decompensated heart failure:Acute Study of Clinical Effectiveness of Nesiritide in Decompensated HeartFailure outcome models |
Khazanie, P.;Heizer, G.M.;Hasselblad, V.;Armstrong, P.W.;Califf, R.M.;Ezekowitz, J.;Dickstein, K.;Levy, W.C.;McMurray, J.J.V.;Metra, M.;Wilson Tang, W.H.;Teerlink, J.R.;Voors, A.A.;O'Connor, C.M.;Hernandez, A.F.;Starling, R.; |
American Heart Journal |
2015-08-01 |
查看 |
| Race and ethnicity influences on cardiovascular and renal events inpatients with diabetes mellitus |
Lewis, E.F.;Claggett, B.;Parfrey, P.S.;Burdmann, E.A.;McMurray, J.J.V.;Solomon, S.D.;Levey, A.S.;Ivanovich, P.;Eckardt, K.U.;Kewalramani, R.;Toto, R.;Pfeffer, M.A.; |
American Heart Journal |
2015-08-01 |
查看 |
| Race and ethnicity influences on cardiovascular and renal events inpatients with diabetes mellitus |
Lewis, E.F.;Claggett, B.;Parfrey, P.S.;Burdmann, E.A.;McMurray, J.J.V.;Solomon, S.D.;Levey, A.S.;Ivanovich, P.;Eckardt, K.U.;Kewalramani, R.;Toto, R.;Pfeffer, M.A.; |
American Heart Journal |
2015-08-01 |
查看 |
|
|
|
